There is a mandatory need for effortless drug administration to young children since the prevalence among them of recurrent wheezing is 15-20%. It is becoming increasingly evident that many of these children respond dramatically well to beta2-agonists and topical steroids; accordingly this sub-group of children should be treated as asthmatics. The dose of topical steroids is critical as opposed to that of beta2-agonists which are often administered in doses well above the minimal effective dose.
INTRODUCTION
The clinical data on the effect of nebulized steroids are a poorly documented area. The question is not whether topical steroids are efficacious drugs, since they are well documented as being highly efficacious in adult patients, in schoolchildren, and even in young children and infants with asthma. But with nebulization we need to know whether the drug is delivered, and at what concentrations. As KEYWORDS: Budesonide, beclomethasone, asthma, children, metered dose, inhalation, nebulizer, steroids, urinary cortisol.
S-33 clinicians we need to be able to compare the doses given by nebulization with a known gold standard such as the metered dose inhaler (MDI) . Only seven studies on these issues have been reported in the literature.
STUDIES OF EFFICACY Beclomethasone
Three of the seven studies concerned beclomethasone dipropionate, the first of which was published seven years ago (Webb et al., 1986) . Although 20 children were admitted, only 13 completed the trial and were included in the results. The study was of randomized, placebo-controlled crossover design with treatment periods of eight weeks. Beclomethasone dipropionate 150p:g was administered an uncertain number of times during the day, nebulized from a Pari Inhalerboy. Active treatment was found to have no significant effect.
In a second, parallel, placebo-controlled study (Storr et al., 1986) , 29 children with asthma were given beclomethasone, 100(ig twice daily from an Acorn nebulizer, for a six-month treatment period. There was a significant improvement in the clinical scoring of wheeziness, as well as in the number of times they had to take a beta2-agonist.
The third study was also of parallel, placebo-controlled design (Carlsen et al., 1988) . Forty-four children were given beclomethasone, 100u.g twice daily from a Pari nebulizer, for an eight-week treatment period. The criteria for inclusion in the trial were that they had been admitted to hospital with acute bronchiolitis and had subsequently suffered from recurrent wheezing -children whom we may consider as asthmatic patients. Treatment had a pronounced effect on symptom scores, the use of rescue medication, and the length of time until the first respiratory illness or the first episode of bronchial obstruction. The increase in time until the next episode of bronchopulmonary obstruction was highly significant (p=0.01). The time to maximal effect of inhaled steroids in these patients was 6-10 weeks which is quite long.
A fair conclusion from these three studies of beclomethasone would be that the nebulized drug may have a clinical effect in the concentrations used. However, we need to know how its efficacy and relative potency compared with the known data from MDIs, before we can recommend this formulation for clinical use.
Budesonide
Subsequent published studies have all employed budesonide in suspension. The first included 23 children with a mean age of 10 months (range, 3-17 months). They were 'infants considered to have severe asthma, because all suffered from recurrent coughing and wheezing unresponsive to nebulized beta-agonist' (Van Bever et al., 1990) . The study was of crossover, placebo-controlled design with four-week treatment periods. Budesonide 500|j,g was given twice daily from an Econeb nebulizer.
Active treatment had no significant clinical effect.
There are, however, several points to note about the study before drawing conclusions. The number of patients was small, increasing the risk of a type II error; the treatment period was short for establishing maximal effect; the nebulizer output was unknown; and, finally, since children who are unresponsive to a beta2-agonist would not normally be termed asthmatic, an alternative diagnosis should probably be considered for some of the children included in the study.
The second budesonide study included 31 children with a mean age of 27 months (range 10-60 months) who had severe asthma and had been prednisone-dependent (a minimum of 0.75mg/kg on alternate days) for the previous two months (Ilangovan et al., 1993 prednisolone. In the run-in period the children were given health scores which improved significantly during the period of active treatment, whether this preceded or followed the placebo period. This study seemed to attest to the efficacy of the drug. BISGAARD: The study documenting equipotency between nebulized suspension and MDI was the one in which the Hudson nebulizer with breath-activated nebulization was used. This is a very efficaceous nebulization. Certainly, a considerable dose of steroid is retained in the nebulizer, but equally certain is that a plastic spacer retains a considerable fraction of the steroid aerosol. Previous studies comparing the dose-delivery from nebulizers and MDI has not to my knowledge used breathactivated nebulizer systems, which may explain the relatively poor performance of the nebulizers.
